SCHEMBL7144473

SCHEMBL7144473

Nc1nc(NCCc2ccc(O)cc2)c(F)c(-c2ccco2)n1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 16/20 0.52
ADORA1 P30542 8/20 0.52
ADORA3 P0DMS8 6/20 0.52
ADORA2B P29275 6/20 0.52
ALDH1A1 P00352 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
MAPK1 P28482 1/20 0.52
TMEM97 Q5BJF2 1/20 0.52
HSD17B10 Q99714 1/20 0.52
HDAC1 Q13547 2/20 0.41
EGFR P00533 1/20 0.41
KDR P35968 1/20 0.41
RAB9A P51151 1/20 0.40
APP P05067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151255 0.87 ADORA2A (0.49) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7151299 0.87 ADORA2A (0.49) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7144746 0.86 ADORA2A (0.53) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5040175 0.84 ADORA2A (0.51) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7146124 0.82 ADORA2A (0.57) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7152930 0.80 ADORA2A (0.49) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL7149808 0.78 ADORA2A (0.47) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7403612 0.78 PDE5A (0.51) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7146934 0.76 APP (0.51) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7151672 0.76 APP (0.51) ADORA2AADORA1ADORA3ADORA2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.